Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways.
Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.